Affinity DataEC50: 26.8nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
President And Fellows Of Harvard College
US Patent
President And Fellows Of Harvard College
US Patent
Affinity DataEC50: 256nMAssay Description:RIP1 kinase assays were performed using ADP-Glo assay (Promega) according to manufacturer's protocol. Reactions were performed in 50 mM HEPES, pH...More data for this Ligand-Target Pair
Affinity DataEC50: 90.5nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
Affinity DataEC50: 324nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
Affinity DataEC50: 26.8nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
Affinity DataEC50: 86.6nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
Affinity DataEC50: >1.00E+5nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
Affinity DataEC50: 2.33E+3nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
Affinity DataEC50: 8.33E+3nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
Affinity DataEC50: 1.05E+4nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
Affinity DataEC50: >1.00E+5nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
Affinity DataEC50: 159nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
Affinity DataEC50: 1.10E+4nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
Affinity DataEC50: 41nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
Affinity DataEC50: 895nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
Affinity DataEC50: 89nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
Affinity DataEC50: 426nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
Affinity DataEC50: 220nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
Affinity DataEC50: 867nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
Affinity DataEC50: 235nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
Affinity DataEC50: 892nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
Affinity DataEC50: 50nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
Affinity DataEC50: 822nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
Affinity DataEC50: 121nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
Affinity DataEC50: 722nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
Affinity DataEC50: 343nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
President And Fellows Of Harvard College
US Patent
President And Fellows Of Harvard College
US Patent
Affinity DataEC50: 93.7nMAssay Description:RIP1 kinase assays were performed using ADP-Glo assay (Promega) according to manufacturer's protocol. Reactions were performed in 50 mM HEPES, pH...More data for this Ligand-Target Pair
Affinity DataEC50: 86.6nMAssay Description:Compound (Ia) was prepared according to the general methods described above. Compound (Ia) and compound A (below) were screened for anti-necrotic act...More data for this Ligand-Target Pair